Nationwide melanoma registry databases in real-world settings: a scoping review protocol

Songchun Yang ^{1,2,3,4}, Dilan Deng ^{1,2,3,4}, Wenrui Lin ^{1,2,3,4}, Xiaozhen Chen ^{1,2,3,4}, Shuang Zhao^{1,2,3,4}, Lixia Lu ^{1,2,3,4}, Yi Xiao ^{1,2,3,4}, Minxue Shen ^{1,2,3,4,5}, Mingliang Chen

^{1,2,3,4}, Xiang Chen ^{1,2,3,4*}, Juan Su ^{1,2,3,4*}

- ¹ Department of Dermatology | Hunan Engineering Research Center of Skin Health and Disease | Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
- ² National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Central South University, Changsha, Hunan 410008, China
- ³ National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
- ⁴ Furong Laboratory, Changsha, Hunan 410008, China
- ⁵ Department of Social Medicine and Health Management, Xiangya School of Public Health, Central South University, Changsha, Hunan 410013, China

* Address for Correspondence:

Department of Dermatology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan 410008, China.

Juan Su, MD, PhD, sujuanderm@csu.edu.cn

Xiang Chen, MD, PhD, chenxiangck@csu.edu.cn

Word count: Abstract 270, Main text 1338 1 figure, 2 tables, 1 appendix Aug 28, 2024

1 ABSTRACT

2 **Introduction:** A patient registry database is an important tool to address a wide range 3 of research questions. Several countries have established nationwide melanoma 4 registry databases. However, there is no report on summarising and comparing these 5 databases. This scoping review aims to answer a broad question on how contemporary 6 nationwide melanoma registry databases were conducted across different countries. 7 **Methods**: The proposed scoping review will follow the guidelines described by the 8 Joanna Briggs Institute manual for evidence synthesis and results will be reported 9 according to the Preferred Reporting Items for Systematic Review and Meta-Analysis 10 extension for Scoping Reviews guideline. PubMed, Embase, Web of Science, 11 ClinicalTrials.gov, and Google will be parallelly and independently searched by two 12 reviewers. We will include nationwide melanoma databases with the aim of 13 continuously and systematically collecting medical records and other relevant 14 information about melanoma patients under routine conditions. The reference list of 15 all included publications will also be screened for additional literature. The literature 16 search will be limited to records after the year 2000 and in English. Two reviewers 17 will independently review the selected literature for information extraction according 18 to a predefined extraction guidance sheet. For databases without relevant literature 19 introductions, we will try contacting the main researchers of the database via email for 20 detailed information. We will provide a brief descriptive analysis of the collected data. 21 **Expected results and implications**: This scoping review will provide an extensive 22 description of how contemporary nationwide melanoma databases were conducted. 23 Findings have the potential to enhance the understanding of melanoma registry 24 databases among researchers in related fields and promote subsequent international 25 collaborations that aim at promoting the clinical practice of melanoma. 26 **Key words**: Melanoma; Registries; Database; Scoping review

27 STRENGTHS AND LIMITATIONS OF THIS STUDY

- 28 \succ This is the first scoping review protocol of summarizing contemporary
- 29 nationwide melanoma databases globally.
- $30 \rightarrow$ Targeted online surveys through email enable us to have a more comprehensive
- 31 understanding of the latest situation of current databases.
- $32 \rightarrow$ We expect to answer a broad question on how contemporary nationwide
- 33 melanoma registry databases were conducted across different countries.
- 34 > Potentially missing relevant databases that have not been insufficiently reported
- 35 is a limitation of the present scoping review.

36 INTRODUCTION

37	Melanoma is a malignant tumour arising from melanocytes. Cutaneous melanoma
38	(including acral melanoma) accounts for the majority of melanoma diagnoses (>90%),
39	with melanomas of mucosal and uveal origin occurring more rarely. ¹ Globally, it is
40	estimated there were 331,647 new cases of cutaneous melanoma and 58,645 deaths
41	caused by cutaneous melanoma in 2022. ² Patient registries are prospective and
42	systematic data collections, which are non-interventional (observational) in nature and
43	reflect care practices under routine conditions (i.e., the real-world settings). ³ A patient
44	registry database might serve as an important tool to address a wide range of research
45	questions, such as evaluating and comparing the clinical effects of different treatments,
46	exploring factors that might affect the prognosis, developing and validating
47	prognostic models and so on. Also, the patients registered in the database can be
48	identified as potential study participants for randomized controlled trials. The real-
49	world evidence generated by these studies has the potential to guide future clinical
50	practice.
51	In recent years, some studies have reported on the development of melanoma
52	registry databases in countries such as Spain, Australia, Denmark, and the
53	Netherlands. ⁴⁻¹⁰ We have performed a preliminary review of published manuscripts or
54	protocols. We have not found a scoping review or knowledge synthesis on
55	contemporary nationwide melanoma registry databases. Therefore, the objective of
56	this scoping review is to answer a broad question on how contemporary nationwide
57	melanoma registry databases were conducted across different countries.

58 METHODS AND ANALYSIS

The proposed scoping review will follow the guidelines described by the Joanna
Briggs Institute (JBI) manual for evidence synthesis.¹¹ Results will be reported
according to the Preferred Reporting Items for Systematic review and Meta-Analysis

62 extension for Scoping Reviews (PRISMA-ScR) guideline.¹²

63 Aims and objectives

- 64 The overall objective of this scoping review is to identify and summarize
- 65 contemporary nationwide melanoma registry databases around the world. The current
- scoping review will be conducted according to the research plan displayed in *Figure*
- 67 *1*. We search for related literature about melanoma registry databases and extract
- 68 relevant items from them. When encountering insufficient reports, we will try
- 69 contacting the person in charge of the database or the corresponding author of the
- relevant publication and inviting them to supplement the information.

71 Patient and public involvement

The present scoping review focuses on the database of melanoma patients, not melanoma patients themselves. Therefore, no patients or the public were recruited for this protocol. Patients or the public were not involved in the design, development or conduct of this current research protocol. We will introduce the main findings of this work through the internet after the publication of this scoping review. This knowledge might be useful to guide the building of subsequent national or regional melanoma registries.

79 Eligibility criteria

80 In the present scoping review, we will include databases that meet the following

81 criteria: (1) it should be a nationwide database of melanoma, and (2) the aim of

82 establishing the database is to continuously and systematically collect medical records

- 83 and other relevant information of melanoma patients under routine conditions, usually
- 84 not limited to a specific research objective. We will exclude the following databases:
- 85 (1) those are not established specifically for melanoma (such as the National Cancer
- 86 Registry); (2) those only cover a few regions of a country; and (3) those are
- 87 temporarily collected to answer one or two research questions and the researchers
- 88 usually do not have a long-term maintenance plan for it. The melanoma patients

89 included in the database could be at any tumor stage and any melanoma subtypes (i.e.,

- 90 cutaneous, acral, mucosal, uveal, etc.). Other inclusion and exclusion criteria are
- 91 summarized in *Table 1*.

92 Information sources

93 In the present scoping review, we will search the melanoma databases through 94 multiple channels, which include: (1) PubMed (pubmed.ncbi.nlm.nih.gov), Embase 95 (www.embase.com), and Web of Science (webofscience.clarivate.cn/wos); (2) the Clinical Trials database (clinicaltrials.gov); and (3) Google (www.google.com). Two 96 97 authors conducted searches on various platforms based on predetermined search terms. 98 The reference list of all included publications will also be screened for additional 99 literature. Studies that are registered in the Clinical Trial database will be searched to 100 identify the melanoma databases that are in the initial stage of establishment. When 101 using the search engine Google for retrieval, the main purpose is to identify the 102 melanoma database that has not been formally reported in any published papers but 103 has established a dedicated website. The pilot searches in PubMed were started on 104 July 28, 2024. Details of the initial search in PubMed is provided in the *Table 2*. 105 Formal searches in all the selected databases will be run on September 15, 2024.

106 Selection process

107 All searched literature will be collated and imported into EndNote software. The 108 duplicates will be removed. The literature search will be limited to records after the 109 year 2000 and in English. Two authors will review the retrieved titles and abstracts 110 independently to identify literature that may contain information on nationwide 111 melanoma databases. The selected papers will be further examined to see if they meet 112 the conditions for formal information extraction. Any inconsistencies that arise during 113 the inclusion and exclusion of literature will be resolved after discussion. The final 114 process of including and excluding literature will be documented and reported in the 115 form of a flowchart in the scoping review. In the end, we will obtain (1) the names of

all retrieved melanoma databases and (2) a list of literature that meets the criteria for

117 information extraction.

118 **Data collection process**

- 119 We have designed a data extraction guidance to clarify the information that needs to
- 120 be extracted from the literature (*appendix 1*). For each retrieved melanoma database,
- 121 if there is literature specifically introducing the database, two authors will
- 122 independently review the related literature for information extraction according to the
- 123 predefined extraction guidance sheet. For databases without relevant literature
- 124 introductions or with insufficient reporting, we will try contacting the main
- 125 researchers of the database via email and inviting them to fill out an online survey
- 126 form regarding the database (https://www.wjx.cn/vm/h5m7Xq1.aspx). Formal email
- 127 invitations are planned to be sent out from October 1, 2024, to November 30, 2024.
- 128 The data obtained through two methods will ultimately be merged into one database.

129 Statistical analysis

- 130 We will provide a brief descriptive analysis of the collected data, including the
- 131 median sample size of different melanoma databases, the proportion of databases
- 132 containing acral melanoma and mucosal melanoma, the proportion of databases that
- 133 have collected biological samples, the proportion of databases that are still collecting
- 134 data prospectively, etc. We will use appropriate figures or charts to display the results.
- 135 All missing values will be reported.

136 **Quality appraisal**

- 137 In the present scoping review, we will not conduct a quality appraisal. This is because
- 138 the objective of this scoping review is to identify all contemporary nationwide
- 139 melanoma databases and summarize their features other than to evaluate the quality of
- 140 data collected in these databases or to evaluate the report quality of the literature
- 141 introducing these databases.

142 Strengths and Limitations

- 143 To the best of our knowledge, this is the first scoping review protocol for
- summarizing contemporary nationwide melanoma databases. The combination of
- 145 direct information extraction from the published literature and targeted online surveys
- 146 through email is expected to enable us to have a more comprehensive understanding
- 147 of the latest situation of current databases. Potentially missing relevant databases that
- 148 have not been insufficiently reported is a limitation of the present scoping review. We
- 149 will search the melanoma databases through multiple channels to minimize such
- 150 omissions. In addition, email surveys might not have an ideal response rate, which
- 151 will limit our ability to obtain more detailed data.

152 Ethics and dissemination

- 153 This study does not directly involve any human participants as it concentrates on the
- 154 database itself. Therefore, ethics committee approval is not required for this study.
- 155 The findings of our review will aim to be published in a peer-reviewed journal.

156 CONCLUSION

- 157 The objective of this scoping review is to identify and summarize contemporary
- 158 nationwide melanoma databases around the world. This review has the potential to
- 159 enhance the understanding of melanoma registry databases among researchers in
- 160 related fields and promote subsequent international collaborations that aim at
- 161 promoting the clinical practice of melanoma.

162 Funding

- 163 This work was supported by the National Key Research and Development Program of
- 164 China (2022YFC2504700) and the National Natural Science Foundation of China
- 165 (grant No. 81974478, 82173009).

166 Contributors

- 167 XC and JS are joint senior authors and designed the study. SY wrote the first draft of
- the manuscript. SY and DD conducted search strategy development. JS and XC
- supervised and obtained funding for the study. JS, XC, and SY had full access to all
- the data in the study and took responsibility for the integrity of the data and the
- accuracy of the data analysis. JS is the guarantor. JS, XC, MC, MS, YX, LL, SZ, XZC,
- 172 WL, and DD critically revised the manuscript. The corresponding author attests that
- all listed authors meet authorship criteria and that no others meeting the criteria have
- been omitted.

175 **Competing interests**

- 176 None declared.
- 177 Patient and public involvement
- 178 Patients and/or the public were not involved in the design, conduct, reporting, or
- 179 dissemination plans of this research.

180 Data availability statement

181 Further information is available from the corresponding author upon request.

182 ORCID iD

- 183 Songchun Yang: 0000-0002-0021-4178
- 184 Dilan Deng: 0009-0008-7629-390X
- 185 Wenrui Lin: 0000-0002-5811-6343
- 186 Shuang Zhao: 0000-0001-7081-6177
- 187 Lixia Lu: 0000-0002-9359-6469

- 188 Yi Xiao: 0000-0002-5124-8378
- 189 Minxue Shen: 0000-0003-0441-9303
- 190 Mingliang Chen: 0000-0003-0755-6848
- 191 Xiang Chen: 0000-0001-8187-636X
- 192 Juan Su: 0000-0001-7035-2560

193 **REFERENCES**

194	1. Long GV, Swetter SM, Menzies AM, et al. Cutaneous melanoma. Lancet
195	2023;402(10400):485-502. doi: 10.1016/s0140-6736(23)00821-8 [published
196	Online First: 2023/07/28]
197	2. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN
198	estimates of incidence and mortality worldwide for 36 cancers in 185
199	countries. CA Cancer J Clin 2024;74(3):229-63. doi: 10.3322/caac.21834
200	[published Online First: 2024/04/04]
201	3. Rustenbach SJ, Heyer K, Reppenhagen K, et al. Registry research in dermatology.
202	Hautarzt 2011;62(3):189-95. doi: 10.1007/s00105-010-2080-y [published
203	Online First: 2011/03/04]
204	4. Ríos L, Nagore E, López JL, et al. Melanoma characteristics at diagnosis from the
205	Spanish National Cutaneous Melanoma Registry: 15 years of experience.
206	Actas Dermosifiliogr 2013;104(9):789-99. doi: 10.1016/j.ad.2013.02.003
207	[published Online First: 2013/04/30]
208	5. Hölmich LR, Klausen S, Spaun E, et al. The Danish Melanoma Database. Clin
209	Epidemiol 2016;8:543-48. doi: 10.2147/clep.S99484 [published Online First:
210	2016/11/09]
211	6. Jochems A, Schouwenburg MG, Leeneman B, et al. Dutch Melanoma Treatment
212	Registry: Quality assurance in the care of patients with metastatic melanoma
213	in the Netherlands. Eur J Cancer 2017;72:156-65. doi:
214	10.1016/j.ejca.2016.11.021 [published Online First: 2016/12/29]
215	7. Gwadry-Sridhar F, McConkey H, Teng X, et al. The national melanoma research
216	registry: A fundamental for disease characterization and epidemiology. Ann
217	Oncol 2018;29:viii460. doi: 10.1093/annonc/mdy289.044

218	8. Ellebaek E, Svane IM, Schmidt H, et al. The Danish metastatic melanoma database
219	(DAMMED): A nation-wide platform for quality assurance and research in
220	real-world data on medical therapy in Danish melanoma patients. Cancer
221	Epidemiol 2021;73:101943. doi: 10.1016/j.canep.2021.101943 [published
222	Online First: 2021/05/08]
223	9. Jobson D, Roffey B, Best R, et al. Developing an Australian Melanoma Clinical
224	Outcomes Registry (MelCOR): a protocol paper. BMJ Open
225	2022;12(9):e062139. doi: 10.1136/bmjopen-2022-062139 [published Online
226	First: 2023/01/24]
227	10. Tejera-Vaquerizo A, Boada A, Puig S, et al. Melanoma Registry of the Spanish
228	Academy of Dermatology and Venereology (REGESMEL): Description and
229	Data in its First Year of Operation. Actas Dermosifiliogr 2024;115(7):663-69.
230	doi: 10.1016/j.ad.2024.02.027 [published Online First: 2024/03/08]
231	11. Pollock D, Peters MDJ, Khalil H, et al. Recommendations for the extraction,
232	analysis, and presentation of results in scoping reviews. JBI Evid Synth
233	2023;21(3):520-32. doi: 10.11124/jbies-22-00123 [published Online First:
234	2022/09/10]
235	12. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews
236	(PRISMA-ScR): Checklist and Explanation. Ann Intern Med 2018;169(7):467-
237	73. doi: 10.7326/m18-0850 [published Online First: 2018/09/05]
238	

Figure 1. The research plan for the scoping review



Database characteristics	Inclusion criteria	Exclusion criteria
Aim of the database	To continuously and systematically collect medical records and other relevant information (such as questionnaires, prognosis, adverse reactions, bio-samples, etc.) of melanoma patients. Usually not limited to a specific research objective.	 Databases that are not established specifically for melanoma, such as the National Cancer Registry. Databases that temporarily collected to answer one or two specific research questions and the researchers usually do not have a long- term maintenance plan for it.
Patients included in the database	 Melanoma of any origin (skin, mucosal, uveal, etc.) Melanoma at any tumor stage 	None
Age limits of patients in the database	All ages	None
Study designs	Cohort study	 Case-control study Cross-sectional study Randomized clinical trial
Publication types	All publication types	Grey literature
Publication status	Published or preprint	None
Countries	All countries	None
Dates	All literature from Jan 1, 2000 onwards	Literature before Jan 1, 2000
Languages	English	Non-English

Table 1. Summary of inclusion and exclusion criteria

Search	Query	Note
#1	melanoma[Title]	Melanoma of any origin (skin, mucosal, uveal, etc.) and at any tumor stage
#2	registry[Title] OR registries[Title] OR database[Title] OR databases[Title]	"registry" and "database" are two keywords of patient registries
#3	2000/1/1:3000/12/12[Publication Date]	All literature from Jan 1, 2000 onwards
#4	"Clinical Trial"[Publication Type] OR "Case- Control Studies"[MeSH] OR "Cross- Sectional Studies"[MeSH]	Case-control studies, cross-sectional studies, and randomized clinical trials will be excluded
#5	#1 AND #2 AND #3 NOT #4	Combine the above search strategies

Table 2. Search strategy terms for PubMed